CSNK2A1 and neoplasm: For instance, epigallocatechin gallate-based NPs carrying both Pt(IV) prodrugs and anti-casein kinase 2 alpha 1 (CSNK2A1) siRNA exerted many beneficial effects by extending the circulation time for Pt-based drugs, increasing the accumulation of the drug within the cancerous cells, decreasing the Pt-drug’s renal side-effects and targeting CSNK2A1, by all of these increasing the tumor’s sensitivity to cisplatin [13].